1. INTRODUCTION {#sec1}
===============

Hematopoiesis is a complex process through which hematopoietic stem cells (HSCs) generate all the cell types found in the blood. This originates during the early stages of embryonic development and continues in the bone marrow (BM) throughout adulthood to preserve homeostasis in the blood system \[[@r1], [@r2]\]. During hematopoiesis, HSCs undergo numerous changes at the epigenetic level and ultimately give rise to all the mature blood cells, such as T cells, macrophages, platelets, *etc*. \[[@r3], [@r4]\].

The interest in the expansion and production of HSCs has increased in recent years. This is partly because of the large number of blood diseases. Blood cancers, and more than 350 immune disorders that cause increased susceptibility to infections are associated with a high percentage of morbidity and mortality in the world \[[@r5]\]. In the past two decades, specific blood cell transfusion or HSC transplantation has been applied in the clinic. However, their maturation as standardized therapy is still an ongoing process \[[@r6]\]. Shortage of immunocompatible HSCs \[[@r7]\], poor *ex vivo* expansion of HSCs \[[@r8]\], and heterogeneity of response to therapy \[[@r5]\] are among the barriers that hinder full utilization of such promising cell therapies in clinics. Therefore, after the derivation of human embryonic stem cells (ESCs) \[[@r9]\] and the discovery of cellular reprogramming \[[@r10]\], much effort has been devoted to obtain HSCs and mature blood cells \[[@r11]\] from human pluripotent stem cells (PSCs). In this review, we discuss the process of hematopoietic differentiation of human PSCs, and we summarize recent reports of successful generation of HSC-like cells by the modulation of TFs and signaling pathways. We will specifically discuss the regulation of two sets of key TFs, HOX and GATA, as master regulators of hematopoiesis.

2. CLINICAL INTEREST IN PLURIPOTENT STEM CELLS IN HEMATOPOIESIS {#sec2}
===============================================================

When treating hematologic malignancies, chemotherapy and/or radiotherapy are used to eliminate malignant cells, but these treatments also harm healthy cells. Thus, HSC-based cell therapy is needed to replace blood cells, wherein successful hematopoietic reconstitution is of paramount importance \[[@r12]\]. Approximately 50,000 allogeneic transplants are performed every year worldwide \[[@r13]\]. Although the number of BM and umbilical cord blood HSC donations is adequate \[[@r14]\], Human Leukocyte Antigen (HLA) compatibility is still one of the most hindering obstacles \[[@r15]\]. Autologous transplantation of *ex vivo* expanded of HSCs is an option to circumvent the need for matched donors and avoid immune rejection and graft *versus* host disease \[[@r16]-[@r20]\]. Nevertheless, *ex vivo* expansion of HSCs remains challenging due to spontaneous differentiation and loss of self-renewal \[[@r8]\].

Due to the above, *de novo* generation of HSCs and functional blood cells from both human ESCs and induced PSCs (iPSCs) has become an attractive alternative to donation-based sources. PSCs have the capacity to self-renew indefinitely and give rise to all cell types found in the human body including the cells that make up the blood system. ESCs have been successfully differentiated into many types of cells *in vitro* since their first derivation \[[@r9]\]. However, ethical issues associated with ESC derivation and the risk of teratoma formation have hampered their advancement to clinical use \[[@r21]\]. Less than a decade later, Takahashi and Yamanaka, by the forced expression of a defined set of TFs (Oct4, Sox2, Klf4, and c-Myc (OSKM)), induced pluripotency in somatic cells and generated iPSCs that are indistinguishable from ESCs in their pluripotency, gene expression and self-renewal capacity. iPSCs are hailed as a promising source of cells for cellular therapy and regenerative medicine (Fig. **[1](#F1){ref-type="fig"}**), because they in principle evade the ethical concerns and risks of immune rejection that are associated with ESCs \[[@r10]\].

3. HEMATOPOIETIC DIFFERENTIATION OF HPSCS {#sec3}
=========================================

Induction of pluripotency and iPSC generation offered valuable access to extensively study early human hematopoiesis. This is in addition to their significance in potentially being a versatile cell source for immunotherapies. Furthermore, differentiating patient-derived iPSC to generate HSCs could allow us to model heritable blood disorders and open unprecedented opportunities to investigate diseased mechanisms, novel therapeutics and high-throughput drug screening (Fig. **[1](#F1){ref-type="fig"}**).

Human PSC differentiation to blood cells has been accomplished using numerous strategies, which include conventional monolayer cultivation, three-dimensional cell aggregates, or Embryoid Bodies (EBs), or through feeder-dependent approaches that involve co-culturing.

A plethora of hematopoietic lineages were derived from hPSCs, including lymphoid cells, erythrocytes, megakaryocytes, platelets and macrophages \[[@r22]\]. These studies offered an insight that would ultimately help to complete our understanding of hemato-endothelial specification of human PSCs.

In the co-culturing method, hPSCs are cultured with murine BM-derived stromal cells using serum-containing medium \[[@r23]\]. Among the different murine BM stromal cells, the OP9 cell line has been shown to yield the most efficient hematopoietic differentiation \[[@r24]\]. OP9 co-culture was used to obtain multipotent hematopoietic progenitors and mature cells including T and B lymphocytes and megakaryocytes \[[@r25]-[@r29]\].

Although this method is attractive since differentiation can be achieved within 9 days without the use of cytokines, its clinical therapeutic potential is diminished due to the use of xenogenic material. In addition, factors like, OP9 cell density, size of hPSC cell aggregates and the quality of Fetal Bovine Serum (FBS) used, make the process variable, thus reducing its value as a method to study signaling pathways involved in the hemato-endothelial transition during the differentiation process.

Directed hematopoietic differentiation of hPSCs using chemically-defined media was also explored.

In this approach, cytokines, morphogens and/or small molecules are used to modulate signaling pathways in hPSCs-derived EBs. A common pattern in these protocols is the use of Wnt agonists and bone morphogenetic protein 4 (BMP4) to induce efficient mesoderm specification, Vascular Endothelial Growth Factor (VEGF) to promote angiogenesis, and hematopoietic cytokine cocktails to drive hematopoiesis \[[@r30], [@r31]\]. This approach was also done in monolayer protocols using extracellular matrix-coated plates. These 2D approaches counteract the variability associated with using EBs. Although these approaches are chemically defined, they have all failed to produce functional multipotent HSCs capable of multilineage long-term engraftment.

Cell identity is endowed by the presence of certain active gene regulatory networks governed by TFs. Since endothelial-hematopoietic transitions in Aorta-Gonad-Mesonephros (AGM) and the generation of HSCs is controlled by cell-specific set of TFs, numerous studies have utilized forced expression of key TFs to direct hPSCs to hematopoietic differentiation \[[@r32]-[@r36]\]. In 2013, Doulatov *et al*., have demonstrated that lineage-restricted CD34^+^CD45^+^ myeloid precursors derived from hPSCs could be reprogrammed into multilineage progenitors that can be expanded *in vitro* and engraft *in vivo* \[[@r32]\]. The TFs HOXA9, ERG, and RAR-related orphan receptor alpha (RORa) promoted self-renewal and multilineage potential *in vitro*. They also allowed *in vitro* maintenance of primitive CD34^+^CD38^-^ cells. Additionally, the group performed transplantation-based cell screening and identified two additional TFs, SOX4 and MYB, that conferred engraftment ability. Hematopoietic cells generated with all five factors could short-term engraft and yield myeloid and erythroid lineages. Generated erythroid precursors silenced embryonic and activated adult globin expression.

In another study in the human system, it was demonstrated that the overexpression of TFs RUNX1, FOSB, SPI1, and GFI1 in human umbilical vein endothelial cells (HUVECs) followed by co-culture with AKT-activated endothelial cells, induced definitive hematopoietic development program \[[@r37]\].

Additionally, in another report, a gain-of-function screening revealed that overexpression of TFs ETV2 and GATA2 or GATA2 and TAL1 activated distinct hematopoietic programs, namely pan-myeloid and erythro-megakaryocytic, respectively \[[@r33]\].

Recently, de novo generation of engraftable HSCs has been achieved in the mouse system \[[@r38]\]. Lis, and colleagues reprogrammed mouse adult endothelial cells to match bone marrow HSCs in their transcriptome. Conditional expression of TFs FOSB, GFI1, RUNX1, and SPI1 (FGRS) in adult mouse endothelial cells co-cultured with vascular niche endothelial cells (VN-ECs) reprogrammed adult endothelial cells into engraftable HSCs (rEC-HSCs). During the conversion, mature endothelial cells transitioned through three subsequent stages. First, endothelial cells began to express Runx1 (induction phase, days 0-8). As a result of FGRS transduction, the cells were able to acquire hematopoietic morphology and markers (specification phase days 8-20). Lastly, the self-renewal and expansion stage included an essential direct cellular contact with vascular niche (expansion phase days 20-28). Interestingly, rEC-HSCs have the capability of long-term self-renewal and engraftment, and a gene expression profile that matched that of adult wild type HSCs. In addition, the same cells can be used for clonally derived engraftment and serial primary and secondary multi-lineage reconstitution, including antigen-dependent adaptive immune function \[[@r38]\].

In 2017, a milestone was reached when Sugimura and colleagues achieved long-term multilineage engraftment of human PSCs-derived hematopoietic progenitor cells \[[@r36]\]. Initially, hemogenic endothelium CD34^+^ cells were magnetically isolated from day 8 human PSCs-derived EBs and then cultured with hematopoietic cytokines. Even though, endothelial-hematopoietic transition was evident (a decrease in *YAP, FOXC1, COUPTFII*, and an increase in hematopoietic lineage gene expression *RUNX1, MYB, GATA2, SCL*), and CD34^+^CD45^+^ cells were emerging in culture, attempts to engraft irradiated immune-deficient recipient mice with these cells were not successful. Based on the assumption that TFs that govern hematopoiesis would be evolutionarily conserved, the group interrogated mouse and human databases of gene expression of fetal liver HSCs relative to hemogenic endothelium and, along with the previously identified factors, a library of 26 TFs was assembled and cloned individually into doxycycline-inducible lentivirus expression system. Three days following the magnetic isolation of hemogenic endothelium from EBs, cells were transduced with the library and 24 hours later transplanted in irradiated immunodeficient recipient mice. Chimerism (presence of human CD45^+^ cells) in peripheral blood of injected mice could be detected for up to 12 weeks following transplantation and doxycycline administration. Furthermore, the examination of bone marrow and thymus revealed a significant presence of human erythroid and myeloid cells and, B and T cells.

Using successfully engrafted human cells as a reference, (identifying what exogenous TFs they carried using PCR amplification), the group was able to identify the essential factors in the library that were indispensable for engraftment. A total of seven factors could be identified, ERG, HOXA5, HOXA9, HOXA10, LCOR, RUNX1, and SPI1. The use of only these seven factors resulted in long-term multilineage engraftment and serial primary and secondary multi-lineage reconstitution.

The significant presence of HOX family members in the seven factors is expected, given their previously identified role in hematopoiesis. HOXA9 is an essential factor in HSCs that promotes self-renewal during embryogenesis and is known to regulate transcription by interacting with numerous enhancers of genes important for hematopoiesis \[[@r39], [@r40]\]. HOXA5 is a direct transcriptional target of the Notch signaling pathway in T cell progenitors along with HOXA9 and HOXA10. This could be indicative of an essential role that these HOX genes may play in T-cell lymphopoiesis \[[@r41]\]. We will discuss HOX genes regulation in more detail in the following sections in this review.

4. REGULATION OF HOX AND GATA TRANSCRIPTION FACTORS AS MASTER REGULATORS OF HEMATOPOIESIS {#sec4}
=========================================================================================

Current protocols of hematopoietic differentiation of PSCs are based on mimicking *in vivo* signaling cascades and factors present during embryonic and adult hematopoiesis. However, a comprehensive understanding of the molecular mechanisms that govern hematopoietic differentiation and specification remains lacking. A large number of regulators work together to orchestrate epigenetic and transcription modifications to direct cellular differentiation \[[@r42], [@r43]\]. Such regulatory mechanisms are important for the proper temporal-spatial expression of master regulators including the HOX \[[@r44]\] and GATA \[[@r45]\] TFs that activate decisive pathways in the developmental process of hematopoietic specification. Furthermore, HOX and GATA factors can be indirectly regulated by other TFs, proteins, and miRNAs, which can also influence cell fate commitment (Fig. **[2](#F2){ref-type="fig"}**). Indeed, this is manifested in the most hematopoietic differentiation protocols where the HOX and GATA family of genes are frequently modulated (Table **[1](#T1){ref-type="table"}**).

4.1. Regulation of HOX Genes {#sec4.1}
----------------------------

The HOX genes encode a family of highly conserved TFs situated in four clusters--HOXA, HOXB, HOXC, and HOXD--in humans. HOX genes are master regulators of cellular differentiation during embryonic development and early hematopoiesis. Their spatio-temporal function suggests HOX genes as key players in hierarchical commitment of cell fate \[[@r44], [@r56]\].

Transcriptional activation of HOX genes is achieved in ESCs in the presence of Retinoic Acid (RA), an important extra- and intra-cellular metabolite involved in diverse biological processes including the stimulation of normal hematopoietic progenitors \[[@r57], [@r58]\]. Using murine ESCs lacking the RA receptor γ (RARγ) or in which the 3\'-RA-responsive element of Hoxa1 has been deleted, Kashyap and colleagues have demonstrated that RARγ is essential for RA-induced HOX transcriptional activation. In addition, deletion of RARγ binding site in the HOXA1 enhancer diminished transcriptional and epigenetic activation of both the *HOXA* and *HOXB* gene clusters. Furthermore, RA/RARγ signaling was shown to be essential for the erasure of histone 3 lysine 27 trimethylation (H3K27me3), a repressive epigenetic mark, from activated HOX genes during ESC differentiation \[[@r59]\].

For function studies, overexpression of Hoxb4 was shown to enable definitive lymphoid-myeloid engraftment potential in mouse ESC-derived hematopoietic progenitors \[[@r60]\]. Additionally, hESCs that overexpress HOXB4 generate greater numbers of cells expressing hematopoietic cell surface markers than wild-type hESCs \[[@r46]\]. However, overexpression of HOXB4 in hESCs failed to confer engraftment on differentiated hematopoietic cells \[[@r61]\]. Multiple studies aimed to elucidate the mechanism by which Hoxb4 upregulation endowed definitive hematopoiesis and engraftment capacity to mESC-derived HSCs. Hoxb4 has been shown to promote the expansion of both adult and mESC-derived HSCs \[[@r62]\]. Its upregulation is associated with an increase in the expression of *c-myc* and *cyclin-D1* \[[@r63]\]. Therefore, Hoxb4 may directly induce the expression of cell cycle regulators and drive cell division forward in adult and ESC-derived HSCs. Genome wide examination of potential targets of Hoxb4 revealed that Hoxb4 binds essential regulators of hematopoiesis including Runx1, stem cell leukemia/T-cell acute lymphocytic leukemia-1 (Scl/Tal1), and Gata2 \[[@r64]\]. Taken together, HOXB4 is likely to be the main regulator of hematopoiesis, which is further illustrated in studies demonstrating its direct interaction with other TFs and co-regulators \[[@r46], [@r65]-[@r67]\].

Hoxa9 is another HOX gene that is important in hematopoiesis. Although H*oxa9* knockout mice are viable, they exhibit smaller thymus and spleen and suffer from a reduction in myeloid cells, lymphocytes, and committed progenitors \[[@r68]\]. In addition, prior gene expression profile comparisons between hESC-derived HSCs and cord blood HSCs revealed HOXA9 to be the most differentially expressed (downregulated in hESCs) gene between the two \[[@r69]\]. HOXA9 overexpression was shown to augment hematopoietic differentiation of hESCs by specifically committing Hemogenic Endothelial (HE) precursor cells into primitive and total CD45^+^ blood cells \[[@r70]\], whereas, in the differentiation from HSCs to mature blood cells, HOXA9 is down-regulated \[[@r40]\]. HOXA9 is one of the most abundant HOX genes in HSCs that work together with HOXB4 to maintain stemness. In hematopoiesis, the progressive loss of expression of these genes sends signals to HSCs to proliferate and starts the downstream lymphoid and myeloid differentiation \[[@r40]\]. Medial HOXA genes including HOXA5, 7 and 9 are suppressed during hematopoietic differentiation of human PSCs \[[@r71]\]. However, simply overexpressing these medial HOXA genes is not sufficient to confer long-term engraftability in human PSC-derived hematopoietic progenitors \[[@r71]\]. These results suggest that the establishment of proper epigenetic state in the HOXA cluster and/or expression of additional regulatory factors are required for context-dependent regulation of HOXA target genes in *bona fide* HSCs (Fig. **[2](#F2){ref-type="fig"}**).

Interestingly, hematopoiesis differentiation is carried out by specific temporal regulation of HOX genes \[[@r72]\]. Many HOX genes (*e.g.* HOXA3, A7, A9 and A13, and HOXB2-B6) are up- and down-regulated during differentiation \[[@r73], [@r74]\]. In terms of down-regulation, the HOXA group has the task of activating the HOX gene repressors to gradually silence the HOX transcription according to the cellular commitment, which yields mature cells with minimal or no expression of HOXA genes \[[@r66], [@r67]\]. An example of a HOX gene regulator is the mix lineage leukemia (MLL) gene, a global epigenetic regulator characterized as a histone methyl transferase (HMT) that contains a DNA methyl transferase (DNMT) homologue domain CxxC that binds to unmethylated CpG residues in HOXA9 locus to protect them from potential DNA methylation \[[@r75]\]. Chromosomal translocation mediated fusion of MLL with TFs, such as MLL-AF4 and MLL-AF9, reinforces a hypomethylated state of CpG of HOXA9 and increases its expression in primitive hematopoiesis. However, the loss of MLL-CxxC domain allows hypermethylation, blocks transcription of HOXA9 gene and facilitates further differentiation \[[@r76]\].

HOX genes are additionally regulated by RNA-mediated mechanisms. Specific transcripts longer than 200 nucleotides called long non-coding RNAs (lncRNAs) can affect hematopoiesis through regulation of messenger RNA (mRNA) stability, chromatin structure or sequestration of regulatory molecules \[[@r77]\] (Fig. **[2](#F2){ref-type="fig"}**). One prominent example is the lncRNA HOTAIRM1 and its isoform HOTAIRM2, located between HOXA1 and HOXA2. HOTAIRM1 and 2 have important roles in ESC differentiation to HSCs, where they are rapidly up-regulated and recruited to HOXA1 and HOXB1 promoter regions to repress transcription and proceed with the proliferation and differentiation to HSCs and progenitors \[[@r78]-[@r80]\]. The same happens in native hematopoiesis, where HOTAIRM1 is up-regulated during myeloid and granulocyte differentiation with the same effect of blocking HOXA repression \[[@r79], [@r81]\]. HOXA transcript at the distal tip (HOTTIP), an additional lncRNA located in the active locus of HOXA13, acts on its target genes through chromosomal looping, which reduces the distance and facilitates the interaction \[[@r82]\]. Through its interaction with WD repeat domain 5 (WDR5) and MLL-1 which is a HMT, HOTTIP lncRNA drives histone H3 lysine 4 trimethylation (H3K4me3) and HOXA gene transcription \[[@r82]\].

4.2. Regulation of GATA Factors {#sec4.2}
-------------------------------

The GATA TF family is composed of 6 members (GATA1-6), which are implicated in several biological processes. The discovery and genetic manipulation of GATA TFs have had a big impact on the understanding of hematopoiesis and development. GATA1 and GATA2 are important for hematopoietic regulation. Although GATA3 is also involved in this process, the molecular mechanisms are still poorly described \[[@r83]\]. GATA1 is a transcriptional activator expressed mainly in megakaryocytes and erythrocytes, but it also participates in the development of eosinophils, mast cells, and dendritic cells \[[@r84], [@r85]\]. GATA2 controls primitive and definitive hematopoiesis, as well as the maintenance of HSCs where it is highly expressed \[[@r86]\]. GATA3 is related to lymphoid lineages differentiation and has a less explored role in HSC quiescence \[[@r87]\].

However, in the context of hematopoiesis, the important roles of GATA1 and GATA2 have been elucidated.

In general, hematopoietic regulation by GATA activity can be viewed as a constant battle between GATA1 and GATA2 to gain chromatin occupancy, where less committed stem cells correlate with a greater presence of GATA2 in chromatin, whereas differentiation is associated with the gain of the territory of GATA1 that displaces GATA2 \[[@r85], [@r88], [@r89]\] (Fig. **[2](#F2){ref-type="fig"}**). GATA2 expression is essential for early embryonic development and early hematopoiesis because it is required for the maintenance and expansion of HSCs and/or multipotent progenitors \[[@r90]-[@r92]\]. Consequently, in early hematopoiesis, GATA2 is recruited to almost all GATA binding sites in chromatin, while GATA1 expression remains low \[[@r93], [@r94]\].

GATA activation can be affected by different factors that can change GATA gene activity in a coordinated fashion, in which positive regulators of GATA2 inhibit GATA1 expression and *vice versa* \[[@r92], [@r95]\]. The GATA proteins are composed of a common conserved C4 zinc finger domain that directly binds DNA and a transactivation domain in the N-terminus that can be positively or negatively regulated \[[@r96], [@r97]\]. Similar to HOX genes, RA exerts a big influence on GATA2 expression by binding with retinoic acid receptor alpha (RARα) expressed in hematopoietic cells. This is mediated by the interaction between the zinc fingers of GATA2 and the DNA-binding domain of RARα in the presence of RA, which allows active transcription in GATA2-bound chromatin sites \[[@r98]\]. On the other hand, the interaction between the N-terminal domain of GATA2 and transcriptional regulators, such as Scl/TAL1, LYL1, LMO2, ERG, FLI-1 or RUNX1, can affect GATA2 chromatin occupancy \[[@r97], [@r99]\]. Such interactions repress GATA2 binding by removing its binding domain from the DNA and vacating the chromatin sites for GATA1 occupancy \[[@r89]\].

Among the GATA1 positive regulators, Friend of GATA-1 (FOG-1) is one of the most important ones that are responsible for the activation and repression of most GATA1 genes. Although FOG-1 does not have a DNA-binding domain, the four FOG-1 zinc fingers can bind to the N-terminus of GATA1, which facilitates GATA1 occupancy at numerous genomic sites to proceed with "the GATA switch" (defined as the displacement of GATA2 and binding of GATA1) \[[@r100], [@r101]\]. FOG-1 recruits the nucleosome remodeling and deacetylation (NuRD) complex, which can be the mechanism through which GATA2 is displaced \[[@r102]\]. Disruption of the FOG1-NuRD association results in a reduction in mature erythroid and megakaryocyte colonies \[[@r102]\]. The histone acetyltransferases (HAT) CREB-binding protein (CBP) and E1A-associated protein p300 (p300) induce acetylation in GATA1, which reinforces its DNA binding to gain genomic occupancy \[[@r103]\]. Together, these co-factors help GATA factors to initiate megakaryocytic and erythroid specification \[[@r104]\].

PU.1 is recognized as an important regulator of cellular communication and immune differentiation by blocking erythroid commitment \[[@r105]\]. In early hematopoiesis, mutual inhibition between GATA1 and PU.1 occurs in progenitor cells, and regulates differentiation into erythroid or myeloid lineages respectively \[[@r106]\]. PU.1 regulates its own expression to drive the myeloid differentiation program through its binding to the upstream regulatory element \[[@r107], [@r108]\]. Targeted disruption of the upstream regulatory element (URE) results in a significant reduction in PU.1 levels and the development of acute myeloid leukemia (AML) \[[@r109]\]. To promote erythroid differentiation, GATA1 binds *PU.1'*s URE and together with DNMT1 mediates repression of PU.1 \[[@r106]\]. In addition, at the *PU.1* promoter, histone 3 lysine 9 (H3K9) methylation and deacetylation as well as the H3K27 methylation occur to further inhibit its transcription \[[@r106], [@r110]\].

The Scl/TAL1 protein, which is involved in HSC maintenance and myeloid lineage differentiation, interacts as a multicomplex (Scl/TAL1:LMO:LDB1) with GATA proteins \[[@r49], [@r111], [@r112]\]. Interestingly, ChIP-sequencing analysis proposes that Scl/TAL1:LMO:LDB is recruited to GATA-bound active transcription sites, and suggests that GATA is a modulator of Scl/TAL1 transcription \[[@r111], [@r113], [@r114]\]. The previously described occupancy competition between GATA1 and GATA2 is responsible of the Scl/TAL1 specific function. This means that the co-occupancy with GATA2 promotes stem cell maintenance, while co-occupancy with GATA1 induces myeloid cell specification \[[@r114], [@r115]\]. Similar to the examples mentioned above, other molecules and TFs interacting with GATA, including GFI1b \[[@r116]\], IKZF1 \[[@r117]\], and RUNX \[[@r118]\], have co-regulator roles in hematopoietic commitment.

4.3. Regulation of HOX and GATA Genes by Small RNAs {#sec4.3}
---------------------------------------------------

Small non-coding RNA of around 22 nucleotides in length, called microRNA (miRNA), interferes in post-transcriptional gene regulation and therefore has a regulatory influence on developmental processes and diseases \[[@r119]\]. miRNA has been found in all cellular compartments including the nucleus, nucleolus, and mitochondria, where it plays different roles in transcription, translation, splicing, DNA repair, and even extracellular signaling events \[[@r120]\]. Around 40% of miRNAs can be found in introns and thus are usually regulated together with their host genes \[[@r120], [@r121]\]. In embryonic hematopoiesis, the miRNA-125 family members are highly expressed mainly in HSCs and progenitors, and their expression decreases with differentiation. Some studies suggest an important role of miRNA-125 in self-renewal of HSCs and its persistent expression in some myeloid and lymphoid leukemias confers resistance to apoptosis and halts differentiation \[[@r15], [@r122], [@r123]\].

The miRNA-196 family, which can be found between the HOXA9 and HOXA10 genes, supports the regulation of cell survival, proliferation, the undifferentiated state and long-term maintenance of HSCs by repressing genes involved in differentiation \[[@r124]\]. This has been demonstrated in HOXA7 and HOXB8, which contain complementary sequences to miRNA-196b and are transcriptionally suppressed in HSCs. Additionally, chromatin immunoprecipitation analysis revealed that the transcriptional repressor, Gfi1, binds directly to the miRNA-196b locus and downregulates its transcription level to permit myeloid differentiation \[[@r124], [@r125]\].

Many miRNAs are implicated in the differentiation of mature blood cells. For example, miRNAs-15, 24, 144, and 451 are required to silence the stemness program of HSCs \[[@r126]-[@r128]\]. As explained above, erythroid lineage differentiation is mainly mediated by GATA1 and GATA2, whose multiple regulatory pathways also involve miRNA-24 and miRNA-27a. The GATA2 protein binds the promoter region of the locus containing miRNA-27a and miRNA-24 (*miR-27a≈24*) and inhibits its transcription in immature erythroid progenitor cells \[[@r133]\]. During erythropoiesis, GATA1 displaces GATA2 from chromatin, including the promoter region of *miR-27a≈24* and promotes its transcription. In a positive feedback loop, mature miR-27a and miR-24 bind the GATA2 mRNA and inhibit its translation, which further promotes erythroid maturation \[[@r129]\]. GATA1 also binds a distal upstream regulatory element of the common locus of miR-144 and miR-451. GATA1 binding recruits the transcription machinery and activates RNA polymerase II-mediated transcription of a common precursor RNA transcript (pre-miRNA) encoding both mature miRNAs. Inhibition of miR-451 in zebrafish embryo using antisense morpholinos yields erythroid progenitors incapable of developing into mature circulating red blood cells \[[@r127]\].

4.4. The Influence of Microenvironment on Signaling Pathways {#sec4.4}
------------------------------------------------------------

We have so far focused on the discussion of epigenetic changes that modulate the activation or repression of master TFs during hematopoiesis. However, numerous factors (including the extracellular environment) can influence cell fate decisions. Another key element in hematopoietic differentiation of human PSCs is the signaling between cells and their microenvironment. Importantly, the interplay between components of the epigenetic machinery and the microenvironment in hematopoiesis may create context-dependent signaling events \[[@r130]\], which make the process more difficult to recreate *in vitro.*

Stem cell factor (SCF), an important hematopoietic factor, is one of the most used cytokines in the medium when HSCs and other hematopoietic progenitors are cultured *in vitro*. SCF promotes hematopoietic differentiation of hPSCs *via* interaction with its receptor c-KIT, a receptor tyrosine kinase under the control of both miR-221 and miR-222. The inhibition of SCF action during hematopoietic differentiation of human PSCs by using a c-KIT antagonist results in reduced multi-lineage potential of the obtained progenitors \[[@r131]-[@r133]\].

Bone morphogenetic protein (BMP) is an important protein that guides the blood formation process \[[@r134]\]. The BMP type 4 (BMP4) expression emerges in the early formation of blood cells in the human yolk sac \[[@r135]\]. In normal hematopoietic differentiation of ESCs, it has been showed that BMP4 first induces mesodermal lineages by activating nuclear Smad proteins. BMP4 signaling is linked to the Wnt signaling pathway, which regulates the caudal gene family (Cdx) and consequently has the capacity to activate transcription of posterior HOX genes \[[@r136]-[@r138]\]. In this linear process, BMP4-Wnt-Cdx-HOX is suggested to cause the activation of HOXA9 and HOXB1, resulting in an improved formation of myeloid colonies \[[@r138], [@r139]\]. This explains why induction protocols (Table **[1](#T1){ref-type="table"}**) include BMP4 and molecules like CHIR99021, which modulate the Wnt/β-catenin pathway \[[@r30], [@r140]\].

Wnt signaling is known to be important for the definitive hematopoiesis potential of KDR^+^ mesodermal progenitors, which give rise to hemogenic endothelium from which HSCs emerge during development \[[@r12], [@r141]\]. Although many studies have elucidated the signaling requirements of the early stages of hematopoietic commitment during *in vitro* differentiation, the gene expression programs and signaling events important for subsequent specification and maturation of HSC from the early progenitors remain obscure. Interestingly, during mouse development β-catenin and Wnt target genes are expressed at higher levels in hemogenic endothelial precursors of HSCs, but are downregulated in HSC \[[@r142]\]. Therefore, it is important to understand the dynamic regulation of Wnt signaling during the specification of human hematopoietic stem/progenitor cells in the future.

5. CURRENT CHALLENGES {#sec5}
=====================

In the pursuit of *de novo* generation of functional HSCs from hPSCs for clinical applications, a number of obstacles remain to be overcome. Aside from the persisting challenge of differentiating hPSCs to HSCs that are capable of long-term engraftment, the safety of the generated blood stem cells needs to be determined. Precise control of the epigenetic changes during the course of hematopoietic differentiation is key in making the resulting cells safe for clinical use. Aberrant regulation of gene expression in hPSC-derived HSCs could lead to hematological malignancies \[[@r143]\]. For example, Enhancer of zeste homolog 2 (EZH2) is highly regulated in normal hematopoiesis in processes such as HSC self-renewal and B cell differentiation \[[@r144]\]. However, EZH2 overexpression or downregulation could lead to tumorigenesis \[[@r145]\]. This includes natural killer/T cell lymphoma \[[@r146]\], follicular lymphoma, T cell acute lymphoid leukemia and metastasis \[[@r147]\]. EZH2 works together with many transcription regulators and miRNAs to catalyze trimethylation of H3K27, which contributes to the silencing of multiple tumor suppressors such as INK4A/ARF and E-cadherin \[[@r147], [@r148]\]. Variability in the epigenome among iPSCs lines has been identified. Nishizawa and colleagues showed that transcriptomic and epigenetic variation contributes to the hematopoietic differentiation capacity (commitment and maturation) of 35 human iPSCs lines and 4 ESCs lines. They correlate the PSC commitment capacity with IGF2 levels that in turn depend on signaling-dependent chromatin accessibility at the mesoderm-related genes \[[@r149]\]. A recent report demonstrated that directed hematopoietic differentiation of hiPSCs using morphogens yields CD45^+^ cells that are epigenetically distinct from wild type human HSCs, when comparing their genome-wide DNA methylation patterns. Additionally, prolonged co-culture with stromal cells did not induce further epigenetic maturation of these iPSC-derived cells \[[@r150]\]. Taken together, with current differentiation protocols, iPSC-derived hematopoietic stem/progenitors seem to be both functionally and epigenetically immature, which brings into question their suitability for clinical application.

CONCLUSION AND FUTURE PERSPECTIVES
==================================

In addition to their unlimited, yet-to-be realized, therapeutic potential, human PSCs make a very useful tool that can be utilized to understand the signaling pathways involved in hematopoiesis. Recently, long term engraftment and multi-lineage differentiation of hPSCs-derived hematopoietic progenitor cells was achieved after screening large numbers of potential TFs that were activated *in vivo* following transplantation in mice \[[@r36]\]. Ideally, the generation of functional HSCs with the same capacity *in vitro* would allow deep interrogation of the differentiation process, and, eventually, the generation of therapeutic grade cells. In addition to using Cas9 as a nuclease for editing DNA sequences, the CRISPR/Cas9 technology can be used as a sequence-specific, non-mutagenic, gene regulation tool when fused with effector proteins (gene activators or repressors). This involves the usage of a deactivated Cas9 that harbors two mutations in its endonuclease domain, rendering it an RNA-guided DNA-binding protein unable to generate single or double DNA breaks \[[@r151]\]. This system can be easily engineered to be doxycycline-inducible, which could allow for multiplexed activation or repression of a large number of endogenous loci at carefully selected time points during the course of *in vitro* differentiation (Fig. **[3](#F3){ref-type="fig"}**). The ability to multiplex and to temporally control gene expression using endogenous loci, makes this system extremely valuable and appropriate to study the process of hPSC hematopoietic differentiation.

Human PSCs represent a promising versatile source of cells for regenerative medicine. The fact that they could be derived from patients' somatic cells and undergo clonal expansion in culture makes them ideal for the regeneration of the blood system. Their potential with regard to treating genetic blood disorders could be augmented when combined with genome editing techniques such as CRISPR/Cas9 \[[@r152]-[@r155]\].

However, two main hurdles limit the translation of iPSC-derived HSCs into cellular therapies. First, the generation of functional iPSC-derived HSCs capable of long-term engraftment and full reconstitution of the blood system. Second, the long-term safety of the generated cells. As mentioned above, HSCs derived from iPSCs remain transcriptionally and epigenetically distinct from cord blood HSCs. The impact of these differences on the safety and functionality of the generated HSCs is yet to be investigated.

After the maunuscript is accepeted for publication, the significant role of GATA2 as a master regulator of hematopoiesis was elucidated in a recent report. Castano and colleagues have demonstrated that GATA2 overexpression during the onset of mesodermal specification, generated hemogenic endothelial progenitors and promoted their further differentiation into hematopoietic progenitor cells. Interestingly, global RNA sequencing and chromatin immunoprecipitation coupled with DNA sequencing, demonstrated that GATA2 directly suppressed cardiac specification genes and activated master hematopoietic regulators, whereas its knockout diminished hematopoietic potential and improved cardiac differentation \[[@r156]\].
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![**Hematopoietic cells engineering for autologous transplantation.** Somatic cells are reprogrammed to pluripotency through modulation of OSKM expression (by TFs overexpression, small molecules in addition to reprogramming factors or integration-free methods). If needed, the genome of patient iPSCs could be edited to correct disease-causing mutations by the CRISPR/Cas9 system. Following differentiation, iPS-derived HSCs or terminally differentiated blood cells could then be transfused back to the patient to achieve the desired functional recovery, or used in high-throughput drug screens.](CG-20-438_F1){#F1}

![**Regulators during hematopoietic differentiation of PSCs.** Hematopoiesis is achieved through the interplay of transcription factors, signaling pathways, and lncRNAs. HOXB4 and HOXA9 promote self-renewal of HSCs through modulating cell cycle regulators. Medial HOXA genes have been shown to be expressed at higher levels in native HSCs compared to PSC-derived HSPCs. Combined upregulation of GATA2 and ETV2 confers pan-myeloid potential in hESC-derived HPCs. Whereas the upregulation of GATA2+TAL1 results in pan-erythroid/megakaryocytic potential. HOTAIRM1/2 upregulation also promotes myeloid differentiation potential by antagonizing HOXA genes. HOXA9 has been shown to be important for lymphoid differentiation.](CG-20-438_F2){#F2}

![**Multiplexed transcriptional gene activation or repression by CRISPR-dCAS9. A)** Doxycycline-inducible dCas9 system could allow for precise temporal modulation of genes during the course of the differentiation process. Guide RNAs (gRNAs) of genes to be activated would be cloned into RNA scaffolds that harbor activator-binding motif, whereas gRNAs targeting genes to be repressed, would be cloned into scaffolds with repressor-recruiting motifs. **B)** The ability to temporally control multiple key TFs using this system could open new opportunities for large scale screenings to ultimately achieve functional HSCs *in vitro.*](CG-20-438_F3){#F3}

###### Summary of hematopoietic differentiation of human pluripotent cells.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Cell Source**      **TF Cocktail**                                                      **Growth Medium**                                         **Destination Cell Type**                                                     **Notes**                                                                                   **Refs.**
  -------------------- -------------------------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- --------------------
  **ESCs**             HOXB4                                                                SCF, IL-3, IL-6, Flt3 ligand, G-CSF, BMP4                 Hematopoietic Progenitor Cells (HPCs) with erythroid and myeloid commitment   \-                                                                                          \[[@r46], [@r47]\]

  **ESCs**             ERG, HOXA9, RORA\                                                    SCF, IL-3, G-CSF, Flt3 ligand, doxycycline.               Multipotent myeloid progenitor\                                               \-                                                                                          \[[@r32]\]
                       +\                                                                                                                             myeloid and erythroid engraftment                                                                                                                                         
                       SOX4 and MYB                                                                                                                                                                                                                                                                                             

  **iPSCs**            None                                                                 *In vivo* teratoma                                        Erythroid, myeloid and lymphoid                                               Oncogenic risk                                                                              \[[@r48]\]

  **ESCs and iPSCs**   GATA2, ETV2 or GATA2, TAL1                                           SCF, bFGF, TPO                                            Pan-myeloid or limited to erythrocytes and megakaryocytes                     \-                                                                                          \[[@r33]\]

  **ESCs**             SCL/TAL1                                                             bFGF                                                      Hematoendothelial progenitors                                                 No *in vivo* reconstitution                                                                 \[[@r35]\]

  **ESCs**             SCL/TAL1                                                             BMP4, VEGF, bFGF, SCF, TPO, Flt3 ligand                   Megakaryocytic precursors, mature megakaryocytes (MKs), and platelets         Trichostatin A (TSA) and hydroxamic acid (SAHA), both mimic the SCL/TAL-induced effects     \[[@r49]\]

  **ESCs and iPSCs**   GATA1, FLI1, TAL1                                                    TPO or EPO                                                Megakaryocytes and erythrocyte progenitors                                    \-                                                                                          \[[@r50]\]

  **ESCs and iPSCs**   EKLF1                                                                bFGF, Y-27632                                             Erythrocytes                                                                  Expressed in the AAVS1 locus                                                                \[[@r11]\]

  **ESCs and iPSCs**   None                                                                 rhSCF, rhFlt3 ligand, rh-IL7                              T-cells                                                                       Based on artificial thymic organoid                                                         \[[@r51]\]

  **iPSCs**            ERG, HOXA5, HOXA9,\                                                  bFGF, VEGF, IL6, IGF-1, IL11, SCF                         HSPCs capable of multilineage engraftment                                     Serially transplantable HSPCs                                                               \[[@r36]\]
                       HOXA10, LCOR, RUNX1, SPI1                                                                                                                                                                                                                                                                                

  **iPSCs**            MLL-AF4                                                              BMP4, bFGF, VEGF, SB431542, SCF, IL3, TPO                 Induced HSPCs (iHSPCs)                                                        Reconstitute hematopoiesis without myeloid bias but prone to leukemic transformation        \[[@r52]\]

  **ESCs and iPSCs**   None                                                                 Forskolin, cAMP, IBMX, SCF, IL-3, IL-5, GM-CSF and EPO.   Cells with HSC-like surface markers                                           cAMP induction decreased oxidative burden in hematopoietic cells                            \[[@r53]\]

  **iPSCs**            None, EB formation and OP-9 co-culture                               BMP4, SCF, Flt3 ligand, IL-6, TPO, IL-3, G-CSF.           Neutrophils                                                                   Changes in expression of GATA-2, SCL/TAL1 and AML1/RUNX1 similar to normal hematopoiesis.   \[[@r54]\]

  **iPSCs**            None, co-cultures or conditioned medium from OP-9 and WEHI-3 cells   Recombinant IL-2, IL-3, Flt3 ligand, and G-CSF            CD34^+^ hematopoietic cells (i CD34^+^ cells)                                 HLA-B4002-lacking i CD34^+^ cells escape cytotoxic T-cell attack                            \[[@r55]\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
